Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Hi WTP,
SCIB1 seems to be very well behaved in clinic; it's performing as intended! Surely that is so rare that pharma are watching like a hawk it to see how far it can go? I mean, how many other drugs perform too or above expectation? We know the usual failure rate is exceptionally high. I get what you are saying though, at some point a deal must be signed. I guess there was a brief window when it was redeveloped just before clinic phase two. I wonder if a deal may have been available then?
Hi Dracula,
This is going to be complicated but I will try my best to be succinct but not short!
Redmile invested on the back of a DD which no doubt included:
Immunobody - SCIB1 phase 1 data.
Moditope - Modi 1 pre-clinical data.
Glycan/Antibody data
Avidimab
I put it to you that Redmile were Scancells first big deal. Without them it was unlikely Scancell would have developed Glycans to the extent they have. Got Modi - 1 to clinic (don't forget how close Lindy and Sally felt Modi 2 was to clinic Q1 2024). Had a shot at the Covidity trial. They may have got SCIB1 to phase 2 but it is a big trial so even if Scancell would have managed it some other way, the trial might not have been so big.
Yet people are asking,' Why don't we get pre-clinical deals like everyone else. Well because SCIB1 and Modi - 1 are actually in clinic so it is impossible to get a pre-clinical deal. Also, I would strongly suggest that we have had a pre-clinical deal of sorts (modi 1) that allows Scancell to maintain it's full rights: Redmile investment.
What do you want? Blood!?!?
No but seriously. It all depends how people look at things.
In regards to trials being completed and an obsession with data. Once again we are in clinic and the company are no doubt swamped with data. Why on earth would they ignore it?
Finally, I am sure that the pharma world understands exactly what Scancell are doing and when the time is right, more deals will get done.
And just one more thing. What have Redmile got from their investment? More impressive SCIB1 data. A Genmab deal. The only thing is that the value is not being shown in current market conditions. But it will.
Please take time to look at the table view and in particular ALL outcome measures. These show what Scancell still need to achieve. Easy eh!?!
https://clinicaltrials.gov/study/NCT04079166?tab=table
Put very simply, Scancell are, 'in trial.' So they are on a predetermined track... The only way is forward until the very end of the trial and data is all important. I am afraid the roller coaster has set off and you may have noticed, there is no emergency stop button. Not at 200mph anyway! The pre-clinical guy has his feet firmly on terrafirmer at the end of the ride looking after everybody else's coats!
Which RNS are we talking about...
PD-L1 you may get your double.
PD-L1 at the behest of a customer which would mean a contract... that'd be very exciting.
Molecular assay combined with repeat validation and it would be full speed ahead.
Worth remembering that due to the complexity and nature of the work being undertaken here, Angle are not likely to keep patting us on the head every week with an RNS.
In the absence of an RNS we know that PD-L1 has been added to the website, been tweeted by Angle AND if you follow the link it is currently occupying the first page... www.angleplc.com This is not guess work it is fact but we have each to draw our own conclusions
DYOR
We also know that Angle are sourcing a third party molecular assay. Getting one to match or adapted might this lead to validation on clinical labs? Also this would help with the NHS study, pelvic mass study and Solaris prostate study?
Lots to play for. So close but yet so far
Worth remembering that following the launch of Portait Flex, AN told us that the DDR assay had been developed for a repeat customer. Also part of Portrait Flex is listed the PD-L1 assay as is DDR. It is under the OncAdapt part of the Angle website but no announcement yet. Coincidence…
Let’s see
Thanks Mia. I have noticed quite a few mentions on Proactive. Owing to both Scancell commercial department and Proactive getting their act together I am guessing? Several stories and links to ensure people are well read on Scancell’s latest. Anybody spending a little time on proactive are likely to come across these news. Makes me wonder if Scancell have an option to build and boost a profile?
Troajan thanks.
2nd article
https://www.proactiveinvestors.co.uk/companies/news/220600/scancell-focuses-on-development-of-two-critical-cancer-fighting-assets-220600.html
Sorry if previously posted it has this morning’s stamp on it
Https://angleplc.com/onc-adapt-laboratories/
Assay development…
Hard to be entirely sure what this means in terms of physical sales but PD-L1 looks interesting.
Should this, will this be RNS’d
Keep an eye on this page
LL
Don’t think so. I think Scancell have been wrong footed by the Auditors delay. They likely have a tight time schedule. Originally planning AGM, Investors Meet and not forgetting presentations. We may have to wait a little for them to make time in a busy schedule is my guess. No drama
Paul Brains,
Having good knowledge about everything rather than an absolute knowledge about one particular facet is where it is at imo. That is not to say that one with an expert knowledge cannot have a general understanding of business and investing. I guess that is why Lindy employs people with so many separate disciplines. I am sure she recognises it is not practical, possible or even required to be an expert at everything...
Well what ever the reason is. What is the point in guessing? Really can not believe it. News issued straight from the horses mouth and it is already being interpreted to 'possible other meanings...' What are people going to make of the actual results? An alien invasion perhaps.
Yes,
OBD flew following raise and previous outstanding results for test. All be it a delayed reaction...
Seem to remember a lot of holders there were jumping into rabbit holes and confusing themselves and others. Hate to think people here are influenced by others. If ever there was an example of making ones own mind up it was OBD.